•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

S02619 Summary:

BILL NOS02619A
 
SAME ASSAME AS A07891-A
 
SPONSORSCARCELLA-SPANTON
 
COSPNSRADDABBO
 
MLTSPNSR
 
Amd §§3221, 4303 & 3216, Ins L
 
Removes restrictions of three-cycle coverage for in vitro fertilization; mandates individual insurance coverage of in vitro.
Go to top

S02619 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         2619--A
 
                               2025-2026 Regular Sessions
 
                    IN SENATE
 
                                    January 21, 2025
                                       ___________
 
        Introduced by Sens. SCARCELLA-SPANTON, ADDABBO -- read twice and ordered
          printed,  and  when printed to be committed to the Committee on Insur-
          ance -- recommitted to the Committee on Insurance in  accordance  with
          Senate  Rule  6, sec. 8 -- committee discharged, bill amended, ordered
          reprinted as amended and recommitted to said committee

        AN ACT to amend the insurance law, in relation to expanded  coverage  of
          in vitro fertilization
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Item (vii) of subparagraph (C) of paragraph 6 of subsection
     2  (k) of section 3221 of the insurance law, as amended  by  section  1  of
     3  part L of chapter 57 of the laws of 2019, is amended to read as follows:
     4    (vii)  Every  large  group  policy delivered or issued for delivery in
     5  this state that provides medical, major medical  or  similar  comprehen-
     6  sive-type coverage shall provide coverage for [three cycles of in-vitro]
     7  in  vitro  fertilization  used in the treatment of infertility. Coverage
     8  may be subject to annual deductibles and coinsurance,  including  copay-
     9  ments,  as  may  be  deemed appropriate by the superintendent and as are
    10  consistent with those established for  other  benefits  within  a  given
    11  policy.  [For  purposes of this item, a "cycle" is defined as either all
    12  treatment that starts when: preparatory medications are administered for
    13  ovarian stimulation for oocyte retrieval with the intent  of  undergoing
    14  in-vitro fertilization using a fresh embryo transfer; or medications are
    15  administered  for  endometrial preparation with the intent of undergoing
    16  in-vitro fertilization using a frozen embryo transfer.]
    17    § 2. Subparagraph (G) of paragraph 3 of subsection (s) of section 4303
    18  of the insurance law, as amended by section 2 of part L of chapter 57 of
    19  the laws of 2019, is amended to read as follows:
    20    (G) Every large group contract that provides medical, major medical or
    21  similar comprehensive-type coverage shall provide  coverage  for  [three
    22  cycles  of  in-vitro]  in  vitro  fertilization used in the treatment of
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD06387-03-6

        S. 2619--A                          2
 
     1  infertility.  Coverage may be subject to annual deductibles and  coinsu-
     2  rance,  including copayments, as may be deemed appropriate by the super-
     3  intendent and as are consistent with those established for  other  bene-
     4  fits  within  a  given  contract.  [For purposes of this subparagraph, a
     5  "cycle" is defined as either all treatment that starts when: preparatory
     6  medications  are  administered  for  ovarian  stimulation   for   oocyte
     7  retrieval  with  the intent of undergoing in-vitro fertilization using a
     8  fresh embryo transfer; or medications are administered  for  endometrial
     9  preparation with the intent of undergoing in-vitro fertilization using a
    10  frozen embryo transfer.]
    11    §  3.  Paragraph 13 of subsection (i) of section 3216 of the insurance
    12  law, as added by chapter 897 of the laws of 1990 and renumbered by chap-
    13  ter 131 of the laws of 1992 and subparagraph (C) as added by  section  3
    14  of  part  L  of  chapter  57  of the laws of 2019, is amended to read as
    15  follows:
    16    (13) (A) Every policy which provides coverage for hospital care  shall
    17  not  exclude  coverage  for hospital care for diagnosis and treatment of
    18  correctable medical conditions otherwise covered by  the  policy  solely
    19  because  the  medical  condition  results  in  infertility[.]; provided,
    20  however that:
    21    (i) subject to the provisions of subparagraph (C) of  this  paragraph,
    22  in  no  case  shall such coverage exclude surgical or medical procedures
    23  provided as part of such hospital care which would correct malformation,
    24  disease or dysfunction resulting in infertility; and
    25    (ii) provided, further however, that  subject  to  the  provisions  of
    26  subparagraph  (C)  of  this  paragraph,  in  no case shall such coverage
    27  exclude diagnostic tests and procedures provided as part of such  hospi-
    28  tal  care that are necessary to determine infertility or that are neces-
    29  sary  in  connection  with  any  surgical  or  medical   treatments   or
    30  prescription  drug coverage provided pursuant to this paragraph, includ-
    31  ing such diagnostic tests and procedures as hysterosalpingogram, hyster-
    32  oscopy, endometrial biopsy, laparoscopy, sono-hysterogram,  post  coital
    33  tests, testis biopsy, semen analysis, blood tests and ultrasound; and
    34    (iii)  provided,  further  however,  every  such policy which provides
    35  coverage for prescription drugs shall  include,  within  such  coverage,
    36  coverage  for  prescription  drugs approved by the federal Food and Drug
    37  Administration for use in the diagnosis and treatment of infertility  in
    38  accordance with subparagraph (C) of this paragraph.
    39    (B) Every policy which provides coverage for surgical and medical care
    40  shall  not  exclude coverage for surgical and medical care for diagnosis
    41  and treatment of correctable medical conditions otherwise covered by the
    42  policy solely because the medical condition results  in  infertility[.];
    43  provided, however that:
    44    (i)  subject  to the provisions of subparagraph (C) of this paragraph,
    45  in no case shall such coverage exclude surgical  or  medical  procedures
    46  which  would  correct  malformation, disease or dysfunction resulting in
    47  infertility; and
    48    (ii) provided, further however, that  subject  to  the  provisions  of
    49  subparagraph  (C)  of  this  paragraph,  in  no case shall such coverage
    50  exclude diagnostic tests and procedures that are necessary to  determine
    51  infertility  or  that  are  necessary in connection with any surgical or
    52  medical treatments or prescription drug coverage  provided  pursuant  to
    53  this  paragraph,  including  such  diagnostic  tests  and  procedures as
    54  hysterosalpingogram,  hysteroscopy,  endometrial  biopsy,   laparoscopy,
    55  sono-hysterogram,  post  coital  tests,  testis  biopsy, semen analysis,
    56  blood tests and ultrasound; and

        S. 2619--A                          3
 
     1    (iii) provided, further however,  every  such  policy  which  provides
     2  coverage  for  prescription  drugs  shall include, within such coverage,
     3  coverage for prescription drugs approved by the federal  Food  and  Drug
     4  Administration  for use in the diagnosis and treatment of infertility in
     5  accordance with subparagraph (C) of this paragraph.
     6    (C)  [Every  policy  that  provides  medical, major medical or similar
     7  comprehensive-type coverage shall  provide  coverage  for]  Coverage  of
     8  diagnostic  and treatment procedures, including prescription drugs, used
     9  in the diagnosis and treatment of infertility as  required  by  subpara-
    10  graphs  (A)  and  (B)  of this paragraph shall be provided in accordance
    11  with the provisions of this subparagraph.
    12    (i) Diagnosis and treatment of infertility shall be prescribed as part
    13  of a physician's overall plan of care and consistent with the guidelines
    14  for coverage as referenced in this subparagraph.
    15    (ii) Coverage may be subject to co-payments, coinsurance  and  deduct-
    16  ibles  as  may  be  deemed  appropriate by the superintendent and as are
    17  consistent with those established for  other  benefits  within  a  given
    18  policy.
    19    (iii) Except as provided in items (vi) and (vii) of this subparagraph,
    20  coverage shall not be required to include the diagnosis and treatment of
    21  infertility  in  connection  with:  (I)  in  vitro fertilization, gamete
    22  intrafallopian tube transfers or zygote intrafallopian  tube  transfers;
    23  (II)  the  reversal  of elective sterilizations; (III) sex change proce-
    24  dures; (IV) cloning; or (V) medical or surgical services  or  procedures
    25  that  are  deemed  to be experimental in accordance with clinical guide-
    26  lines referenced in item (iv) of this subparagraph.
    27    (iv) The superintendent, in  consultation  with  the  commissioner  of
    28  health,  shall  promulgate  regulations which shall stipulate the guide-
    29  lines and standards which shall be used in carrying out  the  provisions
    30  of this subparagraph, which shall include:
    31    (I)  The  identification of experimental procedures and treatments not
    32  covered for the diagnosis and treatment  of  infertility  determined  in
    33  accordance  with the standards and guidelines established and adopted by
    34  the American College of Obstetricians and Gynecologists and the American
    35  Society for Reproductive Medicine;
    36    (II) The identification of the required training, experience and other
    37  standards for health care providers for the provision of procedures  and
    38  treatments  for the diagnosis and treatment of infertility determined in
    39  accordance with the standards and guidelines established and adopted  by
    40  the American College of Obstetricians and Gynecologists and the American
    41  Society for Reproductive Medicine; and
    42    (III)  The  determination  of  appropriate  medical  candidates by the
    43  treating physician in  accordance  with  the  standards  and  guidelines
    44  established  and  adopted  by  the American College of Obstetricians and
    45  Gynecologists and/or the American Society for Reproductive Medicine.
    46    (v)  Coverage  shall  also  include  standard  fertility  preservation
    47  services  when  a  medical  treatment  may  directly or indirectly cause
    48  iatrogenic infertility to an insured. Coverage may be subject to  annual
    49  deductibles  and  coinsurance,  including  copayments,  as may be deemed
    50  appropriate by the superintendent  and  as  are  consistent  with  those
    51  established for other benefits within a given policy.
    52    (vi)  Every  policy  which  provides  coverage for hospital care shall
    53  provide coverage for in vitro fertilization used  in  the  treatment  of
    54  infertility.   Coverage may be subject to annual deductibles and coinsu-
    55  rance, including copayments, as may be deemed appropriate by the  super-

        S. 2619--A                          4
 
     1  intendent  and  as are consistent with those established for other bene-
     2  fits within a given policy.
     3    (vii)  (I)  For  the purposes of this paragraph, "infertility" means a
     4  disease or condition  characterized  by  the  incapacity  to  impregnate
     5  another  person  or  to  conceive, defined by the failure to establish a
     6  clinical pregnancy after twelve months of  regular,  unprotected  sexual
     7  intercourse  or  therapeutic  donor insemination, or after six months of
     8  regular, unprotected sexual intercourse or therapeutic  donor  insemina-
     9  tion  for a female thirty-five years of age or older. Earlier evaluation
    10  and treatment may be warranted based on an individual's medical  history
    11  or physical findings.
    12    [(i)]  (II) For purposes of this [subparagraph] paragraph, "iatrogenic
    13  infertility" means an impairment of  fertility  by  surgery,  radiation,
    14  chemotherapy or other medical treatment affecting reproductive organs or
    15  processes.
    16    [(ii)] (viii) No insurer providing coverage under this paragraph shall
    17  discriminate  based  on an insured's expected length of life, present or
    18  predicted disability, degree of medical dependency, perceived quality of
    19  life, or other health conditions, nor based on personal characteristics,
    20  including age, sex, sexual orientation, marital status or gender identi-
    21  ty.
    22    (D) Every policy that provides  coverage  for  prescription  fertility
    23  drugs and requires or permits prescription drugs to be purchased through
    24  a  network  participating  mail order or other non-retail pharmacy shall
    25  provide the same coverage for prescription  fertility  drugs  when  such
    26  drugs  are  purchased from a network participating non-mail order retail
    27  pharmacy provided that the network participating non-mail  order  retail
    28  pharmacy  agrees  in advance through a contractual network agreement, to
    29  the same reimbursement amount, as well as the same applicable terms  and
    30  conditions, that the insurer has established for a network participating
    31  mail  order or other non-retail pharmacy. In such case, the policy shall
    32  not impose any fee, co-payment, co-insurance, deductible or other condi-
    33  tion on any covered person who elects to purchase prescription fertility
    34  drugs through a network participating  non-mail  order  retail  pharmacy
    35  that it does not impose on any covered person who purchases prescription
    36  fertility  drugs  through  a  network  participating mail order or other
    37  non-retail pharmacy; provided, however,  that  the  provisions  of  this
    38  section  shall not supersede the terms of a collective bargaining agree-
    39  ment or apply to a policy that is the result of a collective  bargaining
    40  agreement  between  an  employer  and a recognized or certified employee
    41  organization.
    42    § 4. This act shall take effect on the first of January next  succeed-
    43  ing  the  date on which it shall have become a law and  shall  apply  to
    44  policies  and contracts issued, renewed, modified, altered or amended on
    45  or after such date.
Go to top